Karo Pharma - Pfizer Collaboration reaches second milestone

Karo Pharma has received a milestone for the RORgamma project amounting to 2 million USD.

“This is the second milestone-payment for RORgamma. Very good news for the project” says Anders Lönner, Chairman of the Board.

For further information, please contact:
Henrik Palm, CFO,
Telephone +46 70 540 40 14 or
E-mail henrik.palm@karopharma.se

The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on May 4, 2016 at 3.00 p.m. CET.


About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.


Documents & Links